Please login to the form below
oncolytic viruses
This page shows the latest oncolytic viruses news and features for those working in and with pharma, biotech and healthcare.
Boehringer bolts on another immuno-oncology company
The company currently has clinical-phase projects ranging across checkpoint inhibitors, oncolytic viruses, cancer vaccines and T-cell engagers, with around half of its early-to-mid-stage pipeline emerging from ... 2006. Other oncolytic virus candidates
Latest news
-
Vyriad inks immunotherapy alliance with Merck/Pfizer
Oncolytic viruses are engineered to selectively replicate within and destroy cancer cells while simultaneously augmenting anti-tumour immunity, and are generally injected directly into tumour sites. ... There’s a lot of activity going on in R&D however,
-
J&J pays $140m upfront for cancer-busting virus firm BeneVir
that the promise of oncolytic viruses will come to fruition when they are used in combination with other cancer immunotherapies. ... The biotech’s website indicates that its oncolytic viruses lend themselves to co-administration with immune checkpoint
-
Sanofi’s latecomer PD-1 gets date for FDA verdict
and oncolytic viruses.
-
Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal
Boehringer buys into oncolytic viruses via 210m ViraTherapeutics deal. Option to acquire the Austrian biotech after phase I trials remains open to Boehringer . ... The deal - valued at up to 210m ($236m) - gives Boehringer joint development rights to
-
BMS to explore new options for its immuno-oncology drug Opdivo
Jean Viallet, global clinical research lead for oncology at BMS, said: “ This collaboration continues to expand our clinical development of Opdivo and explores how oncolytic viruses may provide a complementary mechanism
More from news
Approximately 2 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
cell-based therapies and oncolytic viruses that attack malignant cells directly, and cancer vaccines that try to kickstart an intrinsic immune reaction to the tumour. ... Oncolytic viruses. An oncolytic virus is a virus that preferentially infects and
-
Gene therapy
From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines, oncolytic viruses and chemically modified mRNA. ... In contrast, viruses still
-
Deal Watch December 2016
995+. PsiOxus Therapeutics (UK). BMS (US). Licence. NG-348: preclinical “ armed” oncolytic virus targeting tumour cells. ... technology in the development of immunomodulatory oncolytic viruses.
-
The Maverick: giving medicines away free
His fundamental idea is to create synthetic viruses that can invade cancer cells, destroy them, and then multiply into more viruses to kill the remaining cancerous cells. ... This forms part of a new research area known as oncolytic virology that uses
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Turnstone Biologics bolsters leadership team
Oncolytic viruses and cancer vaccines have the potential to benefits a wide range of patients living with cancer, and the company’s proprietary viral platform technology is at the forefront of ... we advance clinical development of our next-generation
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Products as portfolios: positioning immuno-oncology products
In addition, developments in oncolytic viruses mean the options for patients with certain solid tumours are ever-expanding.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Medical Writers
-
Competitive Salary and Benefits
- Events Manager – Med Comms – Surrey
-
Salary TBC
-
Account Director
-
Excellent benefits
-
New Business Director - PR
-
Competitive Salary and benefits
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
- Senior Account Executive, London, Medical Communications
-
Excellent package
-
Senior Account Manager
-
Negotiable
- Director, Market Access / HEOR - North-West
-
Negotiable
-
Consumer Health Account Director
-
Circa £60, 000 Gym and More
-
Senior Medical Writer
-
Competitive Salary
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
Subscribe to our email news alerts
- Golin opens office in Malaysia
- Synergy Vision to introduce four-day working week
- SWITCHED ONcology. Caregivers Focus Group Highlights. www.switchedoncology.com
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Life Sciences 4.0 - Antony Rawlins
- What is blockchain? - Richard Springham
Latest intelligence
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
- World Diabetes Day: Interaction and impact of diabetes on mental health
- For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
Quick links
Infographics
